Riesgo vascular en pacientes con infección crónica por el VIH-1: controversias con implicaciones terapéuticas, clínicas y pronósticas | Enfermedades Infecciosas y Microbiología Clínica

Article information

La aterosclerosis incrementa el riesgo cardiovascular y la posibilidad de desarrollar un infarto agudo de miocardio (IAM) o un ictus. Los pacientes con infección por el virus de la inmunodeficiencia humana (VIH) presentan con frecuencia alteraciones morfológicas y alteraciones metabólicas (hipercolesterolemia, hipertrigliceridemia, resistencia insulínica, diabetes) que podrían incrementar el riesgo vascular. La frecuente coexistencia de factores de riesgo clásico (dieta aterogénica, tabaquismo, inactividad física, consumo de cocaína), el progresivo incremento de la edad media de los pacientes infectados por el VIH-1 y la polimedicación que reciben, dificulta la estimación del efecto directo que las nuevas terapias pudieran tener sobre este riesgo. Amplios estudios clínicos de cohortes, de naturaleza retrospectiva y diseños diversos, ofrecen resultados contradictorios sobre el riesgo vascular de la población con infección por el VIH. Se precisa un mayor período de observación, y controlar el efecto de los otros factores de riesgo clásico, para depurar el posible efecto deletéreo que las nuevas terapias pudieran tener sobre el riesgo cardiovascular.

Palabras clave:

Dislipemia

Infección por el VIH

Riesgo cardiovascular

Ictus

Infarto de miocardio

Factores deriesgo

Atherosclerosis increases cardiovascular risk and the possibility of developing acute myocardial infarction (AMI) or stroke. Patients infected with human immunodeficiency virus (HIV) often present morphological and metabolic alterations (hypercholesterolemia, hypertriglyceridemia, insulin resistance, diabetes) that can increase vascular risk. The frequent coexistence of classic risk factors (atherogenic diet, smoking, physical inactivity, cocaine abuse), the progressive increase in mean age of HIV-1 infected patients, and the polymedication they receive make it difficult to estimate the direct effect that new therapies may have on cardiovascular risk. Retrospective clinical studies with diverse designs in large cohorts offer contradictory results for cardiovascular risk in the HIV-infected population. Longer observational periods are needed and the effect of other classic risk factors needs to be controlled, in order to establish the possible detrimental effect the new therapies may have on cardiovascular risk in this population.

Key words:

Dyslipidemia

HIV-infected

Cardiovascular risk

Stroke

Myocardial infarction

Risk factors

Full text is only aviable in PDF

Bibliografía

[1.]

B.R. Autran, I. Gorin, M. Lerbowitch.

AIDS in a Haitian woman with cardiac Kaposi’s sarcoma and Whipple’s disease.

Lancet, 1 (1983), pp. 767-769

Medline

[2.]

S. Kaul, M.C. Fishbein, R.J. Siegel.

Cardiac manifestations of acquired immune deficiency syndrome.

Am Heart J, 122 (1991), pp. 535-544

Medline

[3.]

K. Henry, H. Melroe, J. Huebsch, J. Hermundson, C. Levine, L. Swensen.

Severe premature coronary artery disease with protease inhibitors (letter).

Lancet, 351 (1998), pp. 1328

http://dx.doi.org/10.1016/S0140-6736(05)79054-1 | Medline

[4]

G. Behrens, H. Schmidt, Meyer, M. Stoll, R.E. Schmidt.

Vascular complications associated with the use of HIV protease inhibitors (letter).

Lancet, 351 (1998), pp. 1958

http://dx.doi.org/10.1016/S0140-6736(05)78643-8 | Medline

[5.]

B. Gallet, M. Pulik, P. Genet, P. Chedin, M. Hitgen.

Vascular complications associated with use of HIV protease inhibitors (letter).

Lancet, 351 (1998), pp. 1958-1959

http://dx.doi.org/10.1016/S0140-6736(05)78643-8 | Medline

[6.]

D. Vittecoq, L. Escaut, J.J. Monsuez.

Vascular complications associated with the use of HIV protease inhibitors (letter).

Lancet, 351 (1998), pp. 1959

Medline

[7.]

M.P. Dubé, D. Sprecher, W.K. Henry, J.A. Aberg, F.J. Torriani, H.N. Hodis.

Preliminary guidelines for the evaluation and management of dyslipemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.

Clin Infect Dis, 31 (2000), pp. 1216-1224

http://dx.doi.org/10.1086/317429 | Medline

[8]

E. Martínez, C. Fernández-Miranda, I. Conget, S. Moreno, J.M. Santamaría, V. Boix.

Doyma, (2002),

[9.]

P.W. Wilson, R.B. D’Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kamel.

Prediction of coronary heart disease using risk factor categories.

Circulation, 97 (1998), pp. 1837-1847

Medline

[10.]

S.M. Grundy, R. Pasternak, P. Greenland, S. Smith, V. Fuster.

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations.

Circulation, 100 (1999), pp. 1481-1492

Medline

[11.]

J.E. Hokanson, M.A. Austin.

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies.

J Cardiovascul Risk, 3 (1996), pp. 213-219

[12.]

R.S. Rosenson, S. Shott, L. Lu, C.C. Tangney.

Hypertriglyceridemia and other factors associated with plasma viscosity.

Am J Med, 110 (2001), pp. 488-492

Medline

[13.]

Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, S.B. Heymsfield.

The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the third National Health and Nutrition Examination Survey, 1988-1994.

Arch Inter Med, 163 (2003), pp. 427-436

[14.]

J.L. Wall, M. David, C.J. Fichtembaum.

(2002),

[15.]

N. Friis-MΦller, R. Weber, P. Reiss, R. Thiébaut, O. Kirk, A. D’Arminio Monforte.

Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study.

AIDS, 17 (2003), pp. 1179-1193

http://dx.doi.org/10.1097/01.aids.0000060358.78202.c1 | Medline

[16.]

C. Grunfeld, K.R. Feingold.

Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.

N Engl J Med, 327 (1992), pp. 329-337

http://dx.doi.org/10.1056/NEJM199207303270506 | Medline

[17.]

S.A. Riddler, E. Smit, S.R. Cole, R. Li, J.S. Chmiel, A. Dobs.

Impact of HIV infection and HAART on serum lipids in men.

JAMA, 289 (2003), pp. 2978-2982

http://dx.doi.org/10.1001/jama.289.22.2978 | Medline

[18.]

M. Savès, F. Raffi, J. Capeau, W. Rozembaum, J.M. Ragnaud, C. Perronne.

Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

Clin Infect Dis, 34 (2002), pp. 1396-1405

http://dx.doi.org/10.1086/339866 | Medline

[19.]

C. Hadigan, J.B. Meigs, C. Corcoran, P. Rietschel, S. Piecuch, N. Basgoz.

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.

Clin Infect Dis, 32 (2001), pp. 130-139

http://dx.doi.org/10.1086/317541 | Medline

[20.]

S. Mauss, J. Stechel, R. Willers, G. Schmutz, F. Berger, W.O. Richter.

Differentiating hyperlipidaemia associated with antiretroviral therapy.

AIDS, 17 (2003), pp. 189-194

http://dx.doi.org/10.1097/01.aids.0000042944.95433.02 | Medline

[21.]

M. Van der Valk, J.JP. Kastelein, R.L. Murphy, F. Van Leth, C. Katlama, A. Horban.

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-aterogenic lipid profile.

AIDS, 15 (2001), pp. 2407-2414

Medline

[22.]

K.T. Tashima, L. Bausserman, E.N. Alt, E. Aznar, T.P. Flanigan.

Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens.

HIV Clin Trials, 4 (2003), pp. 29-36

http://dx.doi.org/10.1310/hct.2003.4.1.004 | Medline

[23.]

Van Leth F, Phanuphak P, Gazzard B, Cahn P, Wood R, Bloch M, Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). En: Programs and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [Abstract 752].

[24.]

M. Depairon, S. Chessex, P. Sudre, N. Rodondi, N. Doser, J.P. Chave.

Premature atherosclerosis in HIV-infected individuals focus on protease inhibitor therapy.

AIDS, 15 (2001), pp. 329-334

Medline

[25.]

Currier J, Kendall M, Henry K, Torriani F, Storey S, Shikuma C, Carotid imtima-media thickness in HIV-infected and uninfected adults: ACTG 5078. En: Programs and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [Abstract 131].

[26.]

M. Duong, Y. Cottin, L. Piroth, A. Fargeot, I. Lhuiller, M. Bobillier.

Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

Clin Infect Dis, 34 (2002), pp. 523-528

http://dx.doi.org/10.1086/338398 | Medline

[27.]

A. Tabib, T. Greenland, I. Mercier, R. Lorie, J.F. Mornex.

Coronary lesions in young HIV-positive subjects at necropsy.

Lancet, 340 (1992), pp. 730

Medline

[28.]

S. Matetzky, M. Domingo, S. Kar, M. Noc, P.K. Shah, S. Kaul.

Acute myocardial infarction in human immunodeficiency virus-infected patients.

Arch Intern Med, 163 (2003), pp. 457-460

Medline

[29.]

S.D. Holmberg, A.C. Moorman, J.M. Williamson, T.C. Tong, D.J. Ward, K.C. Wood.

Protease inhibitors and cardiovascular outcomes in patients with HIV-1.

Lancet, 360 (2002), pp. 1747-1748

http://dx.doi.org/10.1016/S0140-6736(02)11672-2 | Medline

[30.]

N. Friis-MΦller, C.A. Sabin, R. Weber, A. D’Arminio Monforte, W.M. El Sadr, P. Reiss.

Combination antiretroviral therapy and the risk of myocardial infarction.

N Engl J Med, 349 (2003), pp. 1993-2003

http://dx.doi.org/10.1056/NEJMoa030218 | Medline

[31.]

M.H. David, R. Hornung, C.J. Fichtembaum.

Ischemic cardiovascular disease in persons with human immunodeficiency virus infection.

Clin Infect Dis, 34 (2002), pp. 98-102

http://dx.doi.org/10.1086/324745 | Medline

[32.]

F. Dronda, S. Moreno, M.J. Pérez-Elías, J.L. Casado, A. Antela, A. Moreno.

Vascular disease in HIV-infected patients: A comparative study of two different therapeutic periods (1994-1997 versus 1998-2000).

AIDS, 16 (2002), pp. 1971-1974

Medline

[33.]

S.A. Bozzette, C.F. Ake, H.K. Tam, S.W. Chang, T.A. Louis.

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

N Engl J Med, 348 (2003), pp. 702-710

http://dx.doi.org/10.1056/NEJMoa022048 | Medline

[34.]

D. Torre, A. Pugliese, G. Orofino.

Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in patients with HIV-1 infection.

Clin Infect Dis, 35 (2002), pp. 631-632

http://dx.doi.org/10.1086/341308 | Medline

[35.]

Klein D, Hurley I. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: Additional follow-up. En: Programs and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [Abstract 747].

Indexed in:

Follow us:

Subscribe:

Indexed in:

Follow us:

Subscribe:

Subscribe to our newsletter